CARA: Cara Therapeutics, Inc Analyst Consensus Forecast
Cara Therapeutics, Inc. (CARA) is partnering with Vifor Pharma to promote Korsuva for the relief of dialysis-related pruritus. This daily price chart for the company, where the consensus forecast is set at 8.92, reflects a period of stagnation: legacy royalties generate revenue by inertia, but the portfolio requires updating. The business relies on outsourcing, delegating synthesis and testing to third-party contractors, which creates risks of dependency on external partners.
Analytical breakdowns for Cara Therapeutics, Inc (CARA)
- market price and analyst price targets:
- market capitalization information:
- balance sheet equity data:
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Cara Therapeutics, Inc.|CARA - Long-Term Debt to Capital|Current Liabilities to Capital Cara Therapeutics Inc|CARA - Company Total Debt|Debts to Book Capitalization Cara Therapeutics, Inc|CARA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Cara Therapeutics|Immediate Liquidity caratherapeutics.com
- earnings and valuation multiples information:
CARA - Net Profit|Future Profit Cara Therapeutics, Inc.|CARA - P/E Multiple|Forward P/E Multiple Cara Therapeutics Inc.|CARA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Cara Therapeutics, Inc|CARA - Operating profit EBITDA|Net earnings per share (EPS TTM) Cara Therapeutics|CARA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months caratherapeutics.com|CARA - Net earnings per share growth this year|Projected earnings per share increase next year Cara Therapeutics, Inc.
- issuer revenue and sales details:
Summary company analytics:CARA caratherapeutics.com
Cara Therapeutics, Inc. (CARA) maintains a strong reputation in developing therapies for chronic pruritus, which ensures steady interest from the professional community in the issuer's assets. The consensus price target on GURU.Markets aggregates current expectations from investment firms, allowing investors to track market sentiment dynamics in real time and assess fair equity potential without the time lags associated with traditional reporting.
Competitors of Cara Therapeutics, Inc.
Consensus Target biogen.com BIIB|Analyst Consensus Forecast NBIX (Neurocrine Biosciences, Inc.)|Analyst Consensus Forecast Regencell Bioscience Ltd RGC|AXSM - Price Target Chart|Fair Value Consensus ACAD (ACADIA Corp)|XENE: Analyst Consensus Forecast|vikingtherapeutics.com (VKTX) - Analyst Consensus Forecast|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|PRTA (Prothena Corporation PLC) - Analyst Consensus Forecast|Consensus Target Alector Therapeutics (ALEC)|Analyst Consensus Forecast ANNX|Analyst Consensus Forecast omeros.com (OMER)|Price Target Chart Neurogene Corp NGNE|Fair Value Consensus ACIU|Voyager Therapeutics - Analyst Consensus Forecast|NMRA - Analyst Consensus Forecast|SCLX (Scilex) - Consensus Target|Tevogen Bio Holdings Inc. - Fair Value Consensus|Consensus Target ACOG|CGTX (cogrx.com) - Analyst Forecast Prices|Analyst Consensus Forecast IKT|SAVA (cassavasciences.com) - Fair Value Consensus|Analyst Consensus Forecast ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Average Forecast Price|VTGN - Price Target Chart|Fair Value Consensus OVID (Ovid Therapeutics Inc.)|ABOS: Analyst Consensus Forecast|cervomed.com (CRVO) - Analyst Consensus Forecast|Price Target Chart Alterity Therapeutics Ltd.|Clene Nanomedicine - Forecast Levels Chart|Analyst Consensus Forecast PEPG|JUNS - Average Forecast Price|Relmada Therapeutics - Consensus Target|Analyst Consensus Forecast annovisbio.com ANVS|GRCE: Consensus Target|Firefly Neuroscience, Inc. - Analyst Forecast Prices|KLTO: Analyst Consensus Forecast|NRSN - Analyst Median Target|RVPH (Reviva Pharmaceuticals) - Analyst Consensus Forecast|Consensus Target MetaVia, Inc. (MTVA)|Price Target Chart NeurAxis (NRXS)|Analyst Median Target heliusmedical.com|Passage Bio - Consensus Target|Fair Value Consensus NEUP|Minerva Neurosciences - Analyst Consensus Forecast|Analyst Median Target athira.com ATHA|Addex Therapeutics Ltd (ADXN) - Price Target Chart|Broker Consensus Forecast ALZN|CYCN (Cyclerion Therapeutics Inc.) - Analyst Consensus Forecast|Consensus Target Protagenic (PTIX)|Consensus Target KTTA (Pasithea Therapeutics)|Analyst Median Target cortigent.com|Analyst Consensus Forecast ATXI (Avenue Therapeutics, Inc.)|BCLI - Consensus Target|Chromocell Therapeutics Corporation - Analyst Consensus Forecast|ELYM - Analyst Consensus Forecast|intracellulartherapies.com (ITCI) - Price Target Chart|longboardpharma.com - Fair Value Consensus|MRNS (Marinus Pharmaceuticals, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast NKGen Biotech Inc|Price Target Chart NeuroBo (NRBO)|Sage Therapeutics Inc - Broker Consensus Forecast|Analyst Consensus Forecast SNPX (Synaptogenix, Inc.)|trevena.com (TRVN) - Average Forecast Price|VIGL: Consensus Target|WENA - Analyst Consensus Forecast|Cerevel (CERE) - Price Target Chart
